ArticleDiscover oncology2025
SPINT1-AS1 promotes oxidative damage and apoptosis of gastric cancer cells via the miR-656-3p/PLCXD3 axis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long non-coding RNA SOCS2-AS1 inhibits gastric cancer progression via the miR-324-3p/GRIK3 axis: a mechanistic study.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesIn the study of gastric cancer (GC), long non-coding RNAs (lncRNAs) have been identified and their functions have been partly characterized; however, the specific function of SPINT1 antisense RNA 1 (SPINT1-AS1) in GC remains unclear. This study aimed to investigate the role of SPINT1-AS1 in GC cells and elucidate its downstream molecular mechanisms.
methodsSPINT1-AS1, microRNA-656-3p (miR-656-3p), and phospholipase C, X domain containing 3 (PLCXD3) levels were modulated in GC cells through transfection experiments. Quantitative reverse transcription polymerase chain reaction and Western blot analyses were performed to assess SPINT1-AS1, miR-656-3p, and PLCXD3 levels. The proliferative capacity, apoptosis, invasion, migration, and oxidative stress levels of GC cells were evaluated using 5-ethynyl-2'-deoxyuridine assay, colony formation assay, flow cytometry, Transwell assays, and commercial kits, respectively. Dual-luciferase reporter assay and RNA immunoprecipitation assay were conducted to assess the targeting relationships among SPINT1-AS1, miR-656-3p, and PLCXD3. The impact of SPINT1-AS1 on GC tumor growth was examined in xenograft tumor models.
resultsSPINT1-AS1 and PLCXD3 were found to be downregulated in GC, whereas miR-656-3p was upregulated. SPINT1-AS1 elevation inhibited GC cell proliferation, invasion, migration, and oxidative stress, and promoted apoptosis. SPINT1-AS1 knockdown had opposite effects. The pro-tumor effects induced by SPINT1-AS1 knockdown were reversed by concomitant knockdown of miR-656-3p. Similarly, the inhibitory effects of SPINT1-AS1 elevation on GC malignancy were abrogated by PLCXD3 knockdown. SPINT1-AS1 knockdown suppressed GC tumor growth in mice. SPINT1-AS1 competitively bound to miR-656-3p to mediate PLCXD3 expression.
conclusionsSPINT1-AS1 suppresses GC malignancy through the regulation of the miR-656-3p/PLCXD3 axis. These findings provide robust data supporting the biological functions of lncRNAs in GC and offer potential targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.